On November 2, 2018 Prof. Yechezkel (Chezy) Barenholz will be our invited speaker.
Prof. Barenholz is head of the Liposome and Membrane Research Lab at the Hebrew University-Hadassah Medical School, Jerusalem, Israel and is also the Daniel G. Miller Professor in Cancer Research at Hebrew University of Jerusalem. He has been on the faculty at Hebrew University since 1968 and has been a visiting Professor at leading Universities around the world. His current research focuses on the development of drugs and nano-drugs based on drug delivery systems (DDS) best exemplified by the anticancer Doxil®, the first liposomal drug as well as the first nano-drug approved by the FDA (1995) and used world-wide. Professor Barenholz is an author of >410 scientific publications, cited as of February 2018 >34,000 times, with h-index of 91.
On November 2, 2018 Prof. Dan Peer will be our invited speaker.
His talk will focus on systemic delivery of RNA molecules using targeted nanocarriers to the immune system. Prof. Peer pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in cancer and inflammation.
Professor Dan Peer is the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and the Managing Director of the SPARK program of Translational Medicine at TAU.
IIT Technology Transfer and Venture Factory presented the “Proof of Concept (PoC) investment program” of the VV3TT fund - one of the leading Italian technology transfer funds specialized in robotics, automation and medical devices.
This fund invests in IP and high-tech projects generated by Italian research centers and universities, starting from the prototyping phase. The PoC program makes available the first 75k EU investment which allows the realization of the prototype and the participation in an Executive MBA to better define the tech-business model of the initiative.
MINDED Fellows attended the event and met the speakers afterwards.
On August 13-21, 2018 Alexander Cook took part to the CAS SciFinder Future Leaders at CAS headquarters in Columbus, Ohio.
At the conclusion of the stay in Columbus, Alex will travel to Boston, MA for the 256th ACS National Meeting & Exposition: Nanoscience, Nanotechnology & Beyond, a platform for scientific professionals to present, publish and discuss the most exciting research discoveries in the field.
On June 20, 2018 Dr. Martina Pannuzzo was interviewed on the national TV programme REPORT (RAI3 TV) during which she described the research activities she is involved on a daily basis and how she aims to make an impact through the MINDED programme.
On June 16, 2018, our MINDED Fellow Dr Lucilla Cardinali, gave an oral presentation at the 19th International Multisensory Research Forum, during the Developmental Perspective session. The conference took place in Toronto, Canada.
On June 11, 2018, our MINDED Partner, Prof. Moein Moghimi, visited IIT and presented the following seminar: "Innate Immunity and the Nanoscale Matters".
Prof. Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine (School of Pharmacy) at Newcastle University (UK). He is also an Adjoint Professor at the Department of Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA).
Dr. Shadi Farhangrazi's talk took a close look at the science and business factors impacting design, translation, technology transfer and commercialization of pharmaceutical drugs and ways of improving them. We will take a close look at precision medicine, innovations, therapies and medical technologies making a difference and further take a glance at the possible future of medicine and patient care.
Dr. Shadi Farhangrazi, PhD., MS., MBA, Co-Founder and CEO of SMDG is a global business expert, neuroscientist, and biochemist who has facilitated biotechnology business development, and commercialization for many companies world-wide.
On May 25, 2018 Dr Alessandro Gozzi participated to the group retreat as an Invited Speaker and presented a talk focused on the application of advanced MRI methods to investigate the large-scale neurofunctional architecture of the mouse brain, and describe its modulation by neurodevelopmental and pathological effectors.
Dr Alessandro Gozzi is a Tenure Track Scientist, ERC winner, at IIT Rovereto.
On April 16, 2018, our MINDED Partner, Prof. Dan Peer, visited at IIT and gave the following talk "A universal platform for RNA therapeutics".
Prof. Peer is the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU) funded by the US NIH and the European Union via ERC grant. Prof. Peer is also the Chair of Tel Aviv University Cancer Biology Research Center. He leads the new SPARK program (Center for Translational Medicine) at TAU.
On April 9, 2018 Prof. Didier Letourneur, came to IIT as an Invited Speaker to present to the Minded Fellows a talk focused on industrial and clinical transfers of research works on biomaterials.
Prof. Didier Letourneur is Research Director at CNRS. Since 2014, he is the Director of the Laboratory for Vascular Translational Science affiliated to Inserm and Universities Paris Diderot and Paris North. He also leads the team of Cardiovascular Bioengineering at Bichat Hospital in Paris.
L’Europa premia il progetto MINDED coordinato dall’IIT-Istituto Italiano di Tecnologia con un co-finanziamento pari a oltre 3 milioni di euro, per un totale di oltre 6 milioni di investimento, nel quadro delle Marie Skłodowska-Curie Actions (MSCA).
L’iniziativa permetterà l’avvio di un nuovo piano formativo per giovani scienziati che vogliono identificare terapie innovative per le malattie del neurosviluppo, senza tralasciare gli aspetti sociali ed economici di miglioramento della qualità della vita delle persone.
Formare 24 ricercatori-imprenditori nel settore delle malattie neurologiche dello sviluppo: è l'obiettivo di "Minded", il progetto europeo da 6 milioni di euro co-finanziato dalla Commissione Ue nell'ambito delle Marie Sklodowska Curie Actions e coordinato dall'Italia, con Paolo Decuzzi, dall'Istituto Italiano di Tecnologia (Iit). Al progetto - che prevede l'assunzione di 24 giovani ricercatori da tutto il mondo per svolgere un programma di formazione quadriennale